Loading quotes...
Forecast
There is no analyst data available for this company.
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Kyowa Kirin stock plunges after concerns over US price pressure
Kyowa Kirin’s share fell 11.1% today to ¥2,390 after market participants reassessed the impact of a US pricing agreement in the Medicaid program. Investors fear that expanded rebate requirements could hit sales and Kyowa Kirin’s North America business — a key growth driver — hard. Additional selling pressure came from mostly negative analyst ratings and a weaker Asian market environment; Kyowa Kirin was the biggest loser on the Nikkei 225. » More on de.investing.com
Kyowa Kirin reaches price agreement with US government, stock rises
Kyowa Kirin’s share rose 2.0% to ¥2,681 after the company became part of a price agreement with the US government. Kyowa Kirin is one of nine drugmakers that agreed to lower prices for medicines in the US Medicaid program. The company had earlier reported positive half‑year results and expressed optimism; the stock therefore outperformed the weaker Nikkei 225. » More on de.investing.com
Kyowa Hakko Kogyo pays dividend of 62.00 JPY for 2025
At the annual general meeting on 19 March 2026, Kyowa Hakko Kogyo approved a dividend for 2025 of 62.00 JPY, an increase of 6.90% year on year. The total payout amounts to 30.88 billion JPY and the dividend yield is 2.45%; the share is now trading ex‑dividend. Over three years the share price fell by 17.27%, and the real return including dividends is -17.01%. FactSet analysts expect a dividend of 67.82 JPY for 2026 (estimated yield 2.89%). » More on finanzen.net
Kyowa Kirin takes back Rocatinlimab program from Amgen and plans filings for first half of 2026
Kyowa Kirin has regained control of the global development and commercialization program for Rocatinlimab from Amgen and will submit regulatory applications first in the US and then in Japan. Amgen is exiting the collaboration as part of its portfolio prioritization but will remain the drug substance manufacturer and support an orderly transition. Rocatinlimab showed convincing efficacy in two phase‑III studies involving nearly 1,500 adults with moderate to severe atopic dermatitis; the phase‑III program includes more than 3,300 patients and various populations. The safety profile was consistent, with common, mostly mild adverse events; additional data will be presented at medical congresses. » More on finanzen.net
Kyowa Kirin: Abdul Mullick will be CEO in March 2026 and first non-Japanese company head
The board of Kyowa Kirin appointed Abdul Mullick, currently president and COO, effective after the annual general meeting in March 2026 as president and chief executive officer. Masashi Miyamoto will remain chairman; the change follows the previously introduced dual CEO/COO structure and is intended to make leadership more agile. Mullick, at the company since 2017 and previously in senior roles at Sanofi and Novartis, will continue to work from the global headquarters in Tokyo. » More on de.investing.com
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 687.27m | 0.94% |
| Gross profit | 498.77m | 5.73% |
| Net profit | 119.28m | 25.46% |
| EBITDA | 200.66m | 2.68% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €7.75bn |
Number of shares | 523.59m |
52-week high/low | €16.34 - €3.81 |
Dividend yield | 2.47% |
Dividends TTM | €0.36 |
Beta | 0.42 |
P/E ratio | 15.72 |
PEG ratio | 0.12 |
P/B ratio | 1.49 |
P/S ratio | 2.54 |
Company profile
Kyowa Kirin Co., Ltd. manufactures and markets pharmaceuticals that focuses on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. In addition, it offers PecFent, a nasally administrated spray; POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for the treatment of secondary hyperparathyroidism; Romiplate/Nplate, a genetically recombinant protein for platelet production of thrombopoietin receptors; and SANCUSO for the treatment of nausea and vomiting. Kyowa Kirin Co., Ltd. has an agreement with Amgen Inc. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.
| Name | Kyowa Hakko Kirin |
| CEO | Abdul Hafeez Mullick |
| Headquarters | Tokyo,
ty Japan |
| Website | |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| IPO | 04/01/2000 |
| Employees | 5,161 |
Ticker symbols
| Exchange | Symbol |
|---|---|
Japan Exchange Group | 4151.T |
Pnk | KYKOF |
Frankfurt | KY4.F |
DĂĽsseldorf | KY4.DU |
MĂĽnchen | KY4.MU |